Drug Channels delivers timely analysis and provocative opinions on pharmaceutical economics and the drug distribution system. Drug Channels reaches an engaged, loyal and growing audience of more than 100,000 subscribers and followers. Learn more...

Friday, May 17, 2013

Will Narrowing Pharmacy Networks Squeeze Manufacturers?

Pharmaceutical Executive's May 2013 issue includes Pharmacy Benefit Networks: The Big Squeeze, a new article by yours truly.

The article's first half, excerpted from Chapter 8 of the 2012-13 Economic Report on Retail, Mail, and Specialty Pharmacies, analyzes the narrow pharmacy network trend and highlights its economic appeal to payers and pharmacies.

The article's second half contains my heretofore unpublished views on:
  • How the narrow network revolution will affect pharmaceutical manufacturers’ commercial activities
  • How manufacturers can best prepare for and respond to the risks and challenges of narrow pharmacy networks
Read the article's introduction below. As always, I welcome your comments.

Wednesday, May 15, 2013

How the Pharmacy Industry Ch-ch-changed in 2012

Last week, the IMS Institute for Healthcare Informatics released its official 2012 market data in the report Declining Medicine Use and Costs: For Better or Worse? (Free download with registration.) The report offers loads of interesting stats, but I focus here on the prescription data.

The highlights:
  • Total retail prescription growth was 1.2% in 2012, a rebound from 2011’s especially weak growth of 0.3%.
  • For the first time in nine years, chains lost market share, as they grew more slowly than the overall industry.
  • Supermarkets staged an unexpected comeback, outpacing all other dispensing formats.
  • Independents and mail pharmacies shrank both in absolute size and market share.
Read on for my observations on the 2012 data and the five-year (2008-2012) pharmacy market evolution. Time may change us, but we can't trace time.

Thursday, May 09, 2013

Pharmacist Salaries Hit $117K and Keep Climbing

The Bureau of Labor Statistics (BLS) just released the 2012 Occupational Employment and Wages data. Once again, pharmacist salaries grew faster than did overall wages.

The highlights:
  • In 2012, average gross salary for pharmacists at retail, mail, and specialty pharmacies was $117,000—up 2.7% from 2011.
  • Of the 1,089 occupations in the Occupational Employment Statistics (OES) survey, the “pharmacist” classification ranked 35th in compensation. (The top 10 most highly compensated U.S. occupations are all physician-related.)
  • Pharmacist salaries grew faster than did overall healthcare worker salaries and overall U.S. salaries.
Are pharmacists undervalued? Not if money equals appreciation. Read on for the details.

Tuesday, May 07, 2013

My Controversial 340B Op-Ed

Last week, congressional news site The Hill published my editorial on the 340B drug discount program. Read it here: Hospitals twist prescription assistance program for their own benefit. (The full text is also pasted below).

Some of you will agree with my perspective. Others of you will violently disagree. Please post your comments on Drug Channels. All points of view welcome!

For background, here are my two most recent articles on 340B:

Friday, May 03, 2013

Get Ready for the 2013 Armada Specialty Pharmacy Summit

Next week, I’ll be attending the always-great Armada Specialty Pharmacy Summit in Las Vegas. I enjoy meeting Drug Channels readers, so please introduce yourself. Email me to schedule a one-on-one meeting, especially if you're with a bio/pharm manufacturer and working on specialty channel strategies.

This year's agenda looks especially strong. To help you get ready, below are a selection of Drug Channels articles related to next week's business sessions.

To coincide with the 2013 summit, the Drug Channels Institute is offering a special discount on our 2012–13 Economic Report on Retail, Mail, and Specialty Pharmacies. Use discount code ARMADA2013. Hurry, because the discount expires on May 20, 2013!

See you in Vegas!

Thursday, May 02, 2013

What’s Behind AmerisourceBergen’s Disappointing Oncology Results?

Last week, AmerisourceBergen (NYSE: ABC) reported financial results for the March 2013 quarter. Here’s the press release: AmerisourceBergen Reports $0.87 in Diluted EPS from Continuing Operations, and Revenue of $20.5 Billion for the March 2013 Quarter.

One surprise was the “disappointing performance” in ABC’s oncology business, which accounts for about 40% of its Specialty Group business and 7% of overall revenues.

While management pointed to the sequester, such oncology market changes as practice consolidation and white-bagging are bigger long-term negatives for specialty distributors. Below, I highlight some telling comments by CEO Steve Collis regarding the industry’s evolution.

Specialty distributors face significant risks from changes in the community oncology market. Do ABC’s results foreshadow an oncology market turning point, or simply reflect a short-term government reimbursement cut? Will the specialty distribution and full-line wholesale trade classes blur together? Read on and see what you think.

Tuesday, April 30, 2013

Drug Channels News Roundup: April 2013

Baseball season is finally here! Oil up your glove, put on your cleats, and let's run the bases around this month's news stories. Remember: Sometimes you win, sometimes you lose, and sometimes it rains.

In this issue:
  • Home Run: How Express Scripts and Medco won antirust approval
  • Green Monster: MHA's billion-dollar price tag highlights GPO valuations
  • Free Agents: Consumers are price-shopping for prescriptions
  • Batter Up: A look at the latest national track & trace legislation
Plus, just in time for baseball season, The Onion profiles an electrifying new entrant into the Philadelphia Sports Hall of Fame. Go Phillies!

Monday, April 29, 2013

Medicaid Drug Rebate Program

Time to get ready for IIR’s 18th Annual Summit on the Medicaid Drug Rebate Program (MDRP)! This mega-event will be held at the Chicago Marriott Downtown Magnificent Mile in Chicago, Illinois on September 9-11, 2013.

The MDRP typically sells out, so you should register as soon as possible. The 2013 agenda looks very strong, so I expect this year's event to be extremely popular, too.

Where else can you attend such sessions as "AMPs, NARPs, NADACs, and FULs Oh My!" or play the "GP Geek Game - Wheel of Fortune"? (Yes, these topics are really on this year's jam-packed agenda.) See more details below or visit the MDRP site.

Drug Channels readers can register with promo code XP1858DRC and save $400 off the standard registrations rates. Thanks, IIR!

Friday, April 26, 2013

The Deal with Dirty Data

Today’s guest post is from Becky Holloway, Product Marketing Manager at Revitas. In this informative article, Becky describes the flaws of manual data management and the limits of outsourced data cleansing.

Becky highlights Revitas’s new Online Savings Calculator, a neat tool for assessing the savings from in-sourced prescription level data scrubbing

Please contact Becky Holloway (bholloway@revitasinc.com) with any questions about the article.

Thursday, April 25, 2013

CVS Caremark Renews with Cardinal and McKesson

As expected, CVS Caremark (NYSE: CVS) said "never gonna give you up" and renewed its distribution agreements with Cardinal Health (NYSE: CAH) and McKesson (NYSE: MCK). Cardinal will continue to service the CVS retail stores and distribution centers, while McKesson will continue to service the Caremark mail facilities and some small retail business. Press release links below.

For Cardinal, this news is a big relief following the loss of Express Scripts and Walgreens. As I suggest in Making Sense of ABC-Walgreens-Alliance Boots, the loss of two large, low-profit customers could turn out to be a blessing in disguise.

The renewal also demonstrates wholesalers' value in the brand-name pharmacy supply chain. In theory, the largest self-warehousing chain drugstores and mail pharmacies have the size and scale to perform the functions of drug wholesale distribution. Yet in 2012-13, these larger companies all elected to buy brand-name drugs via a drug wholesaler rather than directly from a manufacturer.

No details about the economics. We can presume that CVS Caremark got a slightly better deal vs. its current agreement, although the economics are not as straightforward as you might expect. Read on for some quick context.

Tuesday, April 23, 2013

The Top 50 Retail Pharmacies, according to Drug Store News

Drug Store News (DSN) just released it latest list of the top pharmacy retailers in the regally-titled PoweRx Players: Profiles of the Kings of Retail Pharmacy. (free download)

I highly recommend the PoweRx list to anyone who competes with, sell to, or interacts with retail pharmacies. This useful resource provides brief profiles of the top 50 companies. These range from Walgreens (#1, with $45.3 billion in prescription sales) to Ritzman Pharmacy (#50, with $57 million in prescription sales). Put another way, the largest chain drugstore dispenses nearly 800 times as much as the 50th largest drugstore.

DSN's top 20 largest pharmacies are shown below. I explain why the DSN list differs from our 2012 Market Share of Top Pharmacies.

Regardless of how you count, it’s good to be the king.

Monday, April 22, 2013

Commercial Contracts and Chargeback Management

The agenda for CBI’s 2013 Commercial Contracts and Chargeback Management forum has just been released. Lots of good topics, including: 340B, chargeback computations, class-of-trade development, and (of course) healthcare reform.

Speakers come from such companies as American Health Care, Amerinet, Apexus/340B Prime Vendor Program, Auxilium Pharmaceuticals, Cardinal Health, Celgene, Compliance Implementation Services, Daiichi Sankyo, Eisai, Eli Lilly & Company, GS1 Healthcare US, Healthcare Supply Chain Association (HSCA), Horizon Pharma, McKesson, Novo Nordisk, Pfizer, PSS World Medical, Purdue Pharma, Revitas, and more.

Drug Channels readers can register with code FZT663 and save $500. Thanks CBI!